Hemocytopenias in Antiphospholipid Syndrome

Montecucco, C.; Caporali, Roberto

doi:10.1007/978-1-4471-3666-8_3

Cited by 2 publications

(1 citation statement)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 An increased level of activated platelets and leukocytes is present in aCL-positive SLE patients, which is frequently associated with thrombocytopenia and leukopenia. 25 A recent investigation indicates that a close association exists in SLE between aCL response and an increased in vivo membrane lipid peroxidation. 26 Such pro-oxidative conditions, induced by UV-irradiation (known to elicit reactive oxygen species) normally exist in skin.…”

Section: Discussionmentioning

confidence: 99%

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE

Toubi

Kessel

Rosner

et al. 2003

Lupus

View full text Add to dashboard Cite

The benefit of combining quinacrine (Qn) with hydroxychloroquine (HCQ) in the treatment of systemic lupus erythematosus (SLE) was previously re-evaluated by us. In our current study we observed that, in 11 active SLE patients (SLEDAI score 5-12), the addition of Qn (100 mg/day) to their existing ongoing therapeutic regimens resulted in a significant attenuation of their previously persistent anticardiolipin antibody (aCL) response. This was in comparison with a matched non-Qn treated control group composed of 14 randomly chosen aCL-positive SLE patients with a similar SLEDAI score 6-10. Prior to Qn treatment the therapeutic regimens of 12 months' duration, included in all cases HCQ (400 mg/day), in many cases prednisone (P, 10-20 mg/day) and in some additional cases immunosuppressive drugs. SLEDAI scores and aCL levels were monitored during the entire follow-up period which totaled 24 months in the study group and 15-18 months in the controls. Along with the beneficial effect of the added Qn on SLEDAI scores, aCL disappearance was documented in eight of 11 patients and remained negative during 8-12 months of follow-up (P = 0.004), compared with such a change in only three of 14 non-Qn treated aCL-positive patients (P = 0.18). We conclude that the added Qn treatment to former established therapeutic protocols may eliminate aCL response in SLE patients. Whether this agent's effect is permanent needs further elucidation.

show abstract

Section: Discussionmentioning

confidence: 99%

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE

Toubi

Kessel

Rosner

et al. 2003

Lupus

View full text Add to dashboard Cite

show abstract

Lupus vasculitis: Differential diagnosis with antiphospholipid syndrome

Golan

2002

Curr Rheumatol Rep

View full text Add to dashboard Cite

The inflammatory process of systemic lupus erythematosus (SLE) vasculitis occurs in up to 56% of patients with SLE, whereas the vaso-occlusive incidence of antiphospholipid syndrome in SLE (which is not exclusive of SLE vasculitis) reaches up to 15%. Both situations can be life-threatening, requiring the appropriate therapeutic approach. Aggressive anti-inflammatory therapy is used in the case of SLE vasculitis and aggressive antithrombotic/anticoagulant treatment in the other. However, often the differential diagnosis between the two entities is difficult to achieve, especially when a tissue biopsy to help establish the diagnosis is topographically difficult to obtain or is clinically contraindicated. Such situations are discussed and appropriate guidelines for a correct diagnosis suggested.

show abstract

Hemocytopenias in Antiphospholipid Syndrome

Cited by 2 publications

References 80 publications

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE

Lupus vasculitis: Differential diagnosis with antiphospholipid syndrome

Contact Info

Product

Resources

About